Skip to main content

The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis

Research Question:
Does the drug Inebilizumab improve disability in patients with a particular type of encephalitis, called anti-N-methyl-D-aspartate receptor encephalitis?

Basic Study Information

Anti-N-methyl-D-aspartate receptor encephalitis is a life-threatening autoimmune disorder for which there are no approved therapies. This study will determine if the drug, Inebilizumab, will improve the disability of patients who have anti-N-methyl-D-aspartate receptor encephalitis. You will be randomized to receive either standard care for this disease, Inelbilizumab, or a placebo. You may be eligible to join if you are 18 years of age or older, have a diagnosis of anti-N-methyl-D-aspartate receptor encephalitis, and have had a recent change in your mental status.

Location: University of Rochester
Study Web URL:
Study Reference #: STUDY00006222

Lead Researcher (Principal Investigator)

Lead Researcher:  Andrew Goodman

Study Contact Information

Study Coordinator: Christine Anne
Phone: (585) 276-3037

Additional Study Details

Learn More About These Conditions

More information about Encephalitis

More information about Encephalitis, Viral

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search